Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Results from a Phase III study in men ages 16 to 26 indicate that the human papillomavirus (HPV) vaccine Gardasil (Merck & Co.) prevented 90% of external genital lesions caused by types 6, 11, 16, and 18 of HPV.

Update on HPV vaccine: Will males be the next ones to receive immunization?